Boston Scientific Settles

With Boston Scientific agreeing to settle three outstanding patent suits with Johnson & Johnson’s Cordis division regarding coronary stents for $1.725 billion, the two companies put behind a seven-year fight over the high value market. 

Both companies hope to take advantage of the opportunity to move on, with Boston Scientific looking to minimize risk in the increasingly competitive stent market and J&J likely to consider more acquisitions.  The move by BSCI is decidedly defensive and is seen by some as reflecting a weakened position (despite the company’s ability to afford the settlement, since it preempts the company from similarly looking at possible acquisitions.


See the MedMarket Diligence Report #C245, “Worldwide Coronary Stents Market, 2008-2017.”

Leave a Reply